Article Text

Download PDFPDF
Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy
  1. Zainab Shahid1,
  2. Elizabeth Packard2,
  3. Andrew Groff2 and
  4. Rohit Jain2
  1. 1 Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania, USA
  2. 2 Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
  1. Correspondence to Mr Andrew Groff, agroff5{at}


Eluxadoline is a novel medication that was approved in the USA in 2015 for the treatment of diarrhoea-predominant irritable bowel syndrome. Due to its unique mechanism of action as both an opioid agonist and antagonist, it has been placed as a schedule IV controlled substance. Since its approval, there have been several cases of eluxadoline-induced pancreatitis reported in the literature. The majority of patients who presented with eluxadoline-induced pancreatitis were reported to have had a prior cholecystectomy. Due to this, the Food and Drug Administration released a warning in 2017 that eluxadoline should no longer be used in patients who do not have a gall bladder. We present a rare case of an adult man without prior cholecystectomy who presented with severe mid-epigastric pain and was found to have eluxadoline-induced pancreatitis.

  • pancreatitis
  • unwanted effects/adverse reactions

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors ZS and EP assisted in writing and revising the manuscript. AG assisted in writing, revising, obtaining the images and submitting the manuscript. RJ obtained patient consent and revised the manuscript. All authors reviewed and approved the final manuscript for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.